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To the Editor: 24 
The prevalence of exercise-induced bronchoconstriction (EIB) is consistently reported to be greater in 25 
athletic individuals than in the general population (1). The reason for this difference remains to be 26 
fully determined, but may be explained by the development of airway hyper-responsiveness arising 27 
from repeated episodes of exercise hyperpnea when performed in noxious environments (2). Equally 28 
however, it is important that the prevalence of EIB is not over-estimated (i.e. false positive) by the 29 
application of overly sensitive diagnostic test methodologies. The aim of this study was to determine 30 
the normative response to a eucapnic voluntary hyperpnoea (EVH) challenge, in cohort of entirely 31 
asymptomatic athletes.  32 
Traditionally EIB was diagnosed using an exercise test, accompanied by a spirometric assessment of 33 
expiratory airflow. A positive result was typically defined by a 10% pre-post challenge reduction in 34 
forced expiratory volume in one second (FEV1), based largely on population studies evaluating the 35 
‘normative’ response to exercise (3). Although this approach is logical, there are several limitations 36 
when employing this methodology in competitive athletes; these include the difficulties inherent to 37 
standardizing and controlling both the effective cardiorespiratory workload and environmental 38 
conditions (4). On this basis, several surrogate means for securing a diagnosis have been 39 
recommended (1), including both direct and indirect bronchoprovocation tests. Of these, EVH testing 40 
is cited as one of the best means to confirm or refute a diagnosis of EIB; principally due to its 41 
simplicity and the fact that it mimics the desiccating stimulus driving the development of EIB (4).  42 
The diagnostic threshold for a positive EVH test was originally established from a cohort of asthmatic 43 
army recruits (n = 90) and ‘normal’ healthy controls (n = 30). A 10% fall in FEV1 was recommended 44 
as the cut-off on the basis of optimising the relationship between specificity (90%) and sensitivity 45 
(63%) and approximates the threshold most commonly utilised with exercise testing (5, 6). The 46 
published data in athletes, is however limited and confounded by a selection bias with inclusion of 47 
individuals with a prior diagnosis of airways disease, history of respiratory symptoms and/or those 48 
prescribed asthma medication (3). Indeed, it is our experience that despite having normal baseline 49 
lung function and no respiratory symptoms, the majority of competitive athletes completing an EVH 50 
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challenge experience a fall in FEV1 following EVH, frequently close to or beyond the 10% diagnostic 51 
cut-off. To describe this further we undertook a retrospective analysis of EVH tests performed in a 52 
large cohort of entirely asymptomatic athletes without a prior diagnosis of asthma or use of asthma 53 
medication. In accordance with previous methods (4) the EVH protocol consisted of breathing a dry 54 
compressed gas mixture (21% O2, 5% CO2, balance N2) at a target ventilation equivalent to 85% 55 
maximum voluntary ventilation for 6 min. Spirometry was performed in triplicate at baseline and in 56 
duplicate at 3, 5, 7, 10, 15 min post EVH.  57 
All athletes assessed (n = 224) were competitive at elite (i.e. either national or international standard) 58 
(n = 161) or recreational level (i.e. training/competing ≥6 hours/week) (n = 63) from a variety of 59 
sporting disciplines: athletics (i.e. competing in track and field events) (n = 71); rugby (n = 61); 60 
badminton (n = 4); boxing (n = 28); soccer (n = 22); hockey (n = 13); swimming (n = 9); rowing (n = 61 
8); and biathlon (n = 8). All had normal predicted lung function values with no evidence of airway 62 
obstruction at rest (Table 1). The majority of athletes (98%) met accepted minimal target ventilation 63 
(i.e. minute ventilation ≥60% MVV) (4). The mean (+/- SD) maximum fall in FEV1 was calculated as 64 
-7.6 ± 6.7% (Figure. 1) with the vast majority of athletes (98.2%) presenting with bronchoconstriction 65 
(i.e. reduction in FEV1) at all time-points post EVH. The mean fall in FEV1 was greater in elite (-8.0 ± 66 
7.2%) than in recreational athletes (-4.2 ± 2.0%) (P<0.01). In the very few athletes eliciting 67 
bronchodilation post challenge (1.8%, n = 4), the ‘improvement’ in FEV1 was only minor (i.e. 68 
approximately 1-2% increase post EVH). When athletes who failed to achieve their target ventilation 69 
were excluded from the analysis (n = 5), the findings remained unchanged (P>0.05) (data not shown). 70 
Likewise, when those with a severe fall in FEV1 (>30%, n = 4) were excluded, the mean fall was not 71 
significantly altered (-7.2 ± 5.9%) (P>0.05).  72 
This study reports, for the first time, what may be considered the pattern of response to an EVH test in 73 
a cohort of athletes. Approximately 20% (n = 44) of this entirely asymptomatic athletic population 74 
would be deemed positive for a diagnosis of EIB based on the accepted 10% cut-off value. Although 75 
markers of airway inflammation or other pathological profiling for ‘asthma’ was not performed, the 76 
findings highlight that a fall in FEV1 >10% is encountered in a significant proportion of entirely 77 
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healthy asymptomatic athletes and thus in many cases may actually represent a variation of the 78 
‘normative’ airway response following exposure to the highly potent stimulus of EVH. Indeed, if an 79 
abnormal response is based on a mean + 2 SD change, as has been previously used to define a cut-off 80 
for EIB when employing an exercise test (8) our data suggests that a 15% cut-off would be a more 81 
appropriate threshold. Of note, in all athletes with >15% fall in FEV1, a sustained reduction in lung 82 
function (i.e. minimum of two consecutive time-points) was observed, thus consistent with current 83 
EIB American Thoracic Society committee guidelines (1). 84 
The decision to initiate treatment for EIB should clearly be decided following the synthesis of clinical 85 
findings and objective test results, however the selection of a ‘correct’ cut-off value for detection of a 86 
condition is vital to guarantee diagnostic accuracy and ensure clinical care is optimised. We have 87 
previously highlighted the poor clinical reproducibility of EVH in athletes when a 10% FEV1 cut-off 88 
threshold is employed (7). Whilst some may consider that a low cut-off threshold ensures that EIB is 89 
‘detected’ and the health and performance of an athlete is optimised, it is equally important to balance 90 
this consideration with both the deleterious impact of unnecessary beta-2 agonist prescription and the 91 
potential for distraction from other potentially important causes of exertional dyspnoea (9). 92 
The findings from this study provide evidence that caution should be applied in the interpretation of a 93 
mild post challenge reduction in lung function (i.e. 10-15% fall in FEV1), certainly when applying 94 
EVH to screen athletic squads. Further work is required to evaluate differences between athletes with 95 
mild (e.g. 10-15% FEV1) and more severe (e.g. >30% FEV1) EIB and in comparison with 96 
commensurate exercise challenge data. Employing inflammatory biomarker analysis and applying 97 
supplementary test methodologies (e.g. impulse oscillometry) would provide additional value in this 98 
setting. 99 
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Table 1.  Clinical characteristics and baseline lung function.  
 
Variables  
Sex (M:F)  178 : 46 
Age (years)  23 ± 4 
Height (cm)  179.6 ± 10.2 
Weight (kg)  83.7 ± 17.5 
BMI (kgm-2)  22.0 ± 4.0 
FEV1 (L)              4.52 ± 0.78 
FEV1 (% predicted)            101.9 ± 11.2 
FVC (L)             5.36  ± 1.03 
FVC (% predicted)            102.2 ± 12.5 
FEV1/FVC (%)              85.1 ± 7.6 
Target ventilation (L/min)           135.7  ± 23.4 
Achieved ventilation (L/min)            121.0 ± 25.2  
Predicted ventilation (%)               89.6 ± 14.4 
Total fall in FEV1 (%)              -7.6 ± 6.7% 
-Elite athlete; fall in FEV1               -8.0 ± 7.2% 
-Recreational athlete; fall in FEV1               -4.2 ± 2.0% 
 Data presented as mean ± SD. n = 224. 
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Figure 1.  Frequency distribution of the maximum reduction in FEV1 in asymptomatic athletes post 
EVH. Broken horizontal line (black) represents current diagnostic threshold (i.e. ≥10% fall in FEV1) 
and broken horizontal line (red) represents proposed revised diagnostic threshold (i.e. ≥15% fall in 
FEV1). Data presented as Mean ± SD.  
 
 
  
 
